Under development for the treatment of PA infection in CF patients. P1 trials are ongoing with development plans for both CF chronic PA infections and non-CF bronchiectasis.

and in many therapeutic indications such as solid tumors, hematologic malignancy and stem cell mobilization. Although a P3 trial in metastatic breast cancer read out negatively in mid-2021, Spexis believes there may be considerable therapeutic potential in other indications and is actively assessing same. We have partnered China rights to Fosun Pharma, a leading Chinese pharmaceutical company, but are seeking additional partnerships and investors to support further development efforts of balixafortide and, potentially, back-up compounds which we have identified and characterized arising from our macrocycle portfolio.